ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma - Quiz - MDSpire

ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma

Dana-Farber Cancer Institute investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial, a first-of-its-kind randomized trial of teclistamab, a BCMA-targeted bispecific antibody, in high-risk smoldering multiple myeloma.

  • By

  • June 14, 2026

  • 4 min

Share

Original Source(s)

ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma

  • by

  • June 14, 2026

Related Content

Financial toxicity as logistical and relational burden across the lifespan during autologous transplant preparation

Differential expression of immune activation markers in T cells from patients with multiple myeloma

Case Report: A diagnostic chameleon of EBV-associated immune dysregulation: HLH unmasking multiple myeloma with subsequent emergence of aggressive B-cell lymphoma